Rallybio Corp Stock Price, News & Analysis

Rallybio Corporation (NASDAQ: RLYB) has made significant strides in its mission to develop therapeutics for rare diseases, as indicated in its recent update. Key milestones include the upcoming Phase 1b proof-of-concept data for RLYB212 expected in Q1 2023 and initial data from a Phase 1 study of RLYB116 anticipated in H2 2023. The company's cash runway has been extended into Q1 2025 following a follow-on offering in November 2022, yielding $55 million in gross proceeds, bolstering its financial position for future developments.

Rallybio Corporation (NASDAQ: RLYB) announced preclinical results showing that low doses of its HPA-1a-specific antibodies, RLYB211 and RLYB212, effectively clear HPA-1a-positive platelets and prevent alloimmunization in mothers, addressing the life-threatening Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT). The study, published in Blood, showed improved outcomes for treated mice, paving the way for potential preventative therapies, as no approved treatments for FNAIT exist. Rallybio anticipates discussing data from its Phase 1b study for RLYB212 in Q1 2023.

Rallybio (Nasdaq: RLYB) and AbCellera (Nasdaq: ABCL) have formed a strategic alliance to develop antibody-based therapeutics for rare diseases. This collaboration combines AbCellera's antibody discovery capabilities with Rallybio's expertise in clinical development. The companies aim to co-develop up to five therapeutic targets, enhancing Rallybio's pipeline and addressing unmet needs in rare metabolic diseases. Both CEOs emphasized the potential for transformative medicines through this partnership.

AbCellera (Nasdaq: ABCL) and Rallybio Corporation (Nasdaq: RLYB) have announced a strategic alliance aimed at developing novel antibody-based therapeutics for rare diseases. This multi-year collaboration combines AbCellera's advanced antibody discovery capabilities with Rallybio's expertise in rare disease clinical development. The partnership will focus on co-developing up to five therapeutic targets, starting with rare metabolic diseases, addressing significant unmet medical needs. Both companies aim to accelerate drug development and improve patient outcomes.

Rallybio Corporation (RLYB), a clinical-stage biotechnology company, announced its participation in a virtual fireside chat at the JMP Securities Hematology and Oncology Summit on December 7, 2022, at 1:40 p.m. ET. The event will be accessible via a live webcast on Rallybio's website, with an archived replay available for 30 days post-event. Founded in January 2018, Rallybio focuses on developing therapies for severe and rare diseases, with a strong portfolio in areas such as hematology and maternal fetal health. The company is headquartered in New Haven, Connecticut.

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company, will participate in two investor conferences: the Jefferies London Healthcare Conference on November 15, 2022, at 8:35 a.m. GMT and the Evercore ISI 5th Annual HealthCONx Conference virtually on November 30, 2022, at 8:25 a.m. EST. Live webcasts will be available on Rallybio's website, with replays accessible for 30 days post-event.

Founded in January 2018, Rallybio focuses on therapies for severe and rare diseases.

Rallybio Corporation (Nasdaq: RLYB) has priced an underwritten public offering of 5,000,001 shares at $6.00 each and pre-funded warrants for up to 3,333,388 shares at $5.9999 each. The total gross proceeds are anticipated to be around $50 million, closing on November 15, 2022. The offering is conducted under the effective shelf registration statement with the SEC, with J.P. Morgan, Cowen, and Evercore ISI as joint lead managers. Investors are advised to refer to the prospectus for detailed information.

Rallybio Corporation (Nasdaq: RLYB) announced a proposed public offering of $75 million in common stock and pre-funded warrants. The offering aims to grant underwriters a 30-day option to purchase an additional 15% of the securities sold. The transaction, which is subject to market conditions, is managed by J.P. Morgan, Cowen, and Evercore ISI. The offering is conducted under an effective shelf registration statement with the SEC, which may affect shareholders. Investors are advised to review the preliminary prospectus for comprehensive details.

Rallybio Corporation (Nasdaq: RLYB) reported financial results for Q3 2022, showing a net loss of $18.4 million and R&D expenses of $12.1 million. The company presented promising preliminary results from the Phase 1b study of RLYB212, demonstrating rapid platelet elimination. Positive topline results from the Phase 1 study of RLYB116 indicated over a 99% reduction in free C5 levels, with potential for less frequent dosing. Rallybio's cash position as of September 30, 2022, was $132.4 million, sufficient to fund operations into Q1 2024.